{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T05:35:03Z","timestamp":1770442503234,"version":"3.49.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Foundation STOPBraintumors"},{"name":"European Community's Seventh Framework Programme","award":["HEALTH-F2-2010-259893"],"award-info":[{"award-number":["HEALTH-F2-2010-259893"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancerletters.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.canlet.2014.09.049","type":"journal-article","created":{"date-parts":[[2014,10,9]],"date-time":"2014-10-09T19:12:22Z","timestamp":1412881942000},"page":"525-535","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"PB","title":["DNA damage response and anti-apoptotic proteins predict radiosensitization efficacy of HDAC inhibitors SAHA and LBH589 in patient-derived glioblastoma cells"],"prefix":"10.1016","volume":"356","author":[{"given":"Lotte M.E.","family":"Berghauser Pont","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kishan","family":"Naipal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenneke J.","family":"Kloezeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subramanian","family":"Venkatesan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"van den Bent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dik C.","family":"van Gent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clemens M.F.","family":"Dirven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Kanaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine L.M.","family":"Lamfers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sieger","family":"Leenstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2014.09.049_bib0010","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJM200101113440207","article-title":"Brain tumors","volume":"344","author":"DeAngelis","year":"2001","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.canlet.2014.09.049_bib0015","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.canlet.2014.09.049_bib0020","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.2174\/092986712802884286","article-title":"The synergistic effects of DNA-targeted chemotherapeutics and histone deacetylase inhibitors as therapeutic strategies for cancer treatment","volume":"19","author":"Stiborova","year":"2012","journal-title":"Curr. Med. Chem"},{"key":"10.1016\/j.canlet.2014.09.049_bib0025","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1111\/j.1582-4934.2011.01296.x","article-title":"Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic","volume":"15","author":"Shabason","year":"2011","journal-title":"J. Cell. Mol. Med"},{"key":"10.1016\/j.canlet.2014.09.049_bib0030","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1748-717X-7-52","article-title":"In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model","volume":"7","author":"Thiemann","year":"2012","journal-title":"Radiat. Oncol"},{"key":"10.1016\/j.canlet.2014.09.049_bib0035","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1097\/MPA.0b013e3181dd63e1","article-title":"Inhibition of radiation-induced DNA repair and prosurvival pathways contributes to vorinostat-mediated radiosensitization of pancreatic cancer cells","volume":"39","author":"Deorukhkar","year":"2010","journal-title":"Pancreas"},{"key":"10.1016\/j.canlet.2014.09.049_bib0040","first-page":"755","article-title":"Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells","volume":"28","author":"Sonnemann","year":"2006","journal-title":"Int. J. Oncol"},{"key":"10.1016\/j.canlet.2014.09.049_bib0045","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijrobp.2004.12.088","article-title":"Modulation of radiation response by histone deacetylase inhibition","volume":"62","author":"Chinnaiyan","year":"2005","journal-title":"Int. J. Radiat. Oncol. Biol. Phys"},{"key":"10.1016\/j.canlet.2014.09.049_bib0050","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.radonc.2013.06.021","article-title":"Radiosensitisation of bladder cancer cells by panobinostat is modulated by Ku80 expression","volume":"108","author":"Groselj","year":"2013","journal-title":"Radiother. Oncol"},{"key":"10.1016\/j.canlet.2014.09.049_bib0055","doi-asserted-by":"crossref","first-page":"11298","DOI":"10.1158\/0008-5472.CAN-06-0049","article-title":"Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer","volume":"66","author":"Geng","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2014.09.049_bib0065","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1093\/neuonc\/not116","article-title":"Serum-free culture success of glial tumors is related to specific molecular profiles and expression of extracellular matrix-associated gene modules","volume":"15","author":"Balvers","year":"2013","journal-title":"Neuro-Oncol"},{"key":"10.1016\/j.canlet.2014.09.049_bib0070","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/B978-0-12-394387-3.00002-1","article-title":"Mechanisms of resistance to histone deacetylase inhibitors","volume":"116","author":"Lee","year":"2012","journal-title":"Adv. Cancer Res"},{"key":"10.1016\/j.canlet.2014.09.049_bib0075","first-page":"637","article-title":"Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review)","volume":"33","author":"Emanuele","year":"2008","journal-title":"Int. J. Oncol"},{"key":"10.1016\/j.canlet.2014.09.049_bib0080","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/bjc.2013.21","article-title":"Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair","volume":"108","author":"Groselj","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2014.09.049_bib0085","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s11060-011-0604-7","article-title":"Vorinostat modulates cell cycle regulatory proteins in glioma cells and human glioma slice cultures","volume":"105","author":"Xu","year":"2011","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.canlet.2014.09.049_bib0090","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00280-009-1004-y","article-title":"MTT assays cannot be utilized to study the effects of STI571\/Gleevec on the viability of solid tumor cell lines","volume":"64","author":"Sims","year":"2009","journal-title":"Cancer Chemother. Pharmacol"},{"key":"10.1016\/j.canlet.2014.09.049_bib0095","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv. Enzyme Regul"},{"key":"10.1016\/j.canlet.2014.09.049_bib0100","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1096\/fj.07-099234","article-title":"DEVD-NucView488: a novel class of enzyme substrates for real-time detection of caspase-3 activity in live cells","volume":"22","author":"Cen","year":"2008","journal-title":"FASEB J."},{"key":"10.1016\/j.canlet.2014.09.049_bib0105","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1182\/blood-2012-04-420968","article-title":"High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)-mediated inhibition of platelet production","volume":"120","author":"Thon","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2014.09.049_bib0110","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev"},{"key":"10.1016\/j.canlet.2014.09.049_bib0115","author":"Coe"},{"key":"10.1016\/j.canlet.2014.09.049_bib0120","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","article-title":"Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1","volume":"17","author":"Verhaak","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2014.09.049_bib0125","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/0008-5472.CAN-03-2630","article-title":"Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275","volume":"64","author":"Camphausen","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2014.09.049_bib0130","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1158\/0008-5472.CAN-09-4244","article-title":"Wip1 directly dephosphorylates gamma-H2AX and attenuates the DNA damage response","volume":"70","author":"Cha","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2014.09.049_bib0135","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.freeradbiomed.2010.02.033","article-title":"DNA-PKcs deficiency leads to persistence of oxidatively induced clustered DNA lesions in human tumor cells","volume":"48","author":"Peddi","year":"2010","journal-title":"Free Radic. Biol. Med"},{"key":"10.1016\/j.canlet.2014.09.049_bib0140","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11060-005-5953-7","article-title":"CHEK2 mutations in primary glioblastomas","volume":"74","author":"Sallinen","year":"2005","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.canlet.2014.09.049_bib0145","doi-asserted-by":"crossref","first-page":"R47","DOI":"10.1186\/bcr3147","article-title":"Low expression levels of ATM may substitute for CHEK2\/TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer","volume":"14","author":"Knappskog","year":"2012","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.canlet.2014.09.049_bib0150","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1089\/cbr.2009.0629","article-title":"HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells","volume":"24","author":"Chen","year":"2009","journal-title":"Cancer Biother. Radiopharm"},{"key":"10.1016\/j.canlet.2014.09.049_bib0155","doi-asserted-by":"crossref","first-page":"34272","DOI":"10.1074\/jbc.273.51.34272","article-title":"Bcl-2 prevents caspase-independent cell death","volume":"273","author":"Okuno","year":"1998","journal-title":"J. Biol. Chem"},{"key":"10.1016\/j.canlet.2014.09.049_bib0160","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat. Rev. Drug Discov"},{"key":"10.1016\/j.canlet.2014.09.049_bib0165","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1046\/j.1440-1711.1999.00824.x","article-title":"Molecular mechanisms of ionizing radiation-induced apoptosis","volume":"77","author":"Watters","year":"1999","journal-title":"Immunol. Cell Biol"},{"key":"10.1016\/j.canlet.2014.09.049_bib0170","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1016\/j.cellsig.2011.07.017","article-title":"Bcl-xL phosphorylation at Ser49 by polo kinase 3 during cell cycle progression and checkpoints","volume":"23","author":"Wang","year":"2011","journal-title":"Cell. Signal"},{"key":"10.1016\/j.canlet.2014.09.049_bib0175","doi-asserted-by":"crossref","first-page":"32657","DOI":"10.1074\/jbc.M110.140350","article-title":"Anti-apoptotic protein BCL2 down-regulates DNA end joining in cancer cells","volume":"285","author":"Kumar","year":"2010","journal-title":"J. Biol. Chem"},{"key":"10.1016\/j.canlet.2014.09.049_bib0180","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.4161\/cc.9.14.12354","article-title":"MCL-1 localizes to sites of DNA damage and regulates DNA damage response","volume":"9","author":"Jamil","year":"2010","journal-title":"Cell Cycle"},{"key":"10.1016\/j.canlet.2014.09.049_bib0185","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1073\/pnas.0307708100","article-title":"Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1","volume":"101","author":"Gui","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2014.09.049_bib0190","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/ijc.20774","article-title":"Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid","volume":"114","author":"Camphausen","year":"2005","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2014.09.049_bib0195","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1158\/1078-0432.CCR-08-0643","article-title":"Postradiation sensitization of the histone deacetylase inhibitor valproic acid","volume":"14","author":"Chinnaiyan","year":"2008","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.canlet.2014.09.049_bib0200","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1158\/1535-7163.MCT-06-0022","article-title":"Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci","volume":"5","author":"Munshi","year":"2006","journal-title":"Mol. Cancer Ther"},{"key":"10.1016\/j.canlet.2014.09.049_bib0205","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1158\/1541-7786.MCR-11-0587","article-title":"Suberoylanilide hydroxamic acid as radiosensitizer through modulation of RAD51 protein and inhibition of homology-directed repair in multiple myeloma","volume":"10","author":"Chen","year":"2012","journal-title":"Mol. Cancer Res"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383514005904?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383514005904?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T17:53:11Z","timestamp":1538157191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383514005904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0304383514005904"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2014.09.049","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DNA damage response and anti-apoptotic proteins predict radiosensitization efficacy of HDAC inhibitors SAHA and LBH589 in patient-derived glioblastoma cells","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2014.09.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}